Literature DB >> 11021590

IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice.

K Song1, Y Chang, G J Prud'homme.   

Abstract

Intramuscular (i.m.) injection of a plasmid encoding human carcinoembryonic antigen (CEA) elicited immunity against transplanted syngeneic (C57BL/6) CEA-positive Lewis lung carcinoma (CEA/LLC) cells, but tumors still appeared in all mice. In wild-type mice, coinjection of an IL-12 plasmid markedly enhanced anti-CEA humoral, T-helper-1 and cytotoxic T lymphocyte (CTL) responses, and resistance to a CEA/LLC tumor challenge such that 80% of mice remained tumor free. Injection of the IL- 12 plasmid alone was not protective. To analyze immune requirements, we immunized gene knockout (KO) mice of C57BL/6 background, deficient in either CD3, CD4, CD8, interferon gamma (IFNgamma), perforin or Fas ligand (FasL). Only CD3+ mice expressing both CD4 and CD8, which appear equally important, as well as IFNgamma and perforin, could fully resist a tumor challenge. IL-12 stimulated CTL activity, which was strictly CD3/CD8/perforin-dependent. FasL-KO mice had normal CTL activity and tumor resistance, indicating that only the perforin lytic pathway was involved. CD4-KO and IFNgamma-KO mice still generated CTLs. CEA-stimulated IFNgamma production occurred in both CD4- or CD8-KO mice and in both cases was augmented by IL-12. In IFNgamma-KO mice, IL-12 still enhanced anti-CEA antibody production but only moderately restored impaired DTH and tumor resistance. We conclude that the immune requirements for tumor rejection are stringent, involving multiple mechanisms which are all enhanced by IL-12.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11021590     DOI: 10.1038/sj.gt.3301274

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  8 in total

1.  MC32 tumor cells acquire Ag-specific CTL resistance through the loss of CEA in a colon cancer model.

Authors:  Sang-Yeul Lee; Jeong-Im Sin
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  T Cells and Regulated Cell Death: Kill or Be Killed.

Authors:  Johan Spetz; Adam G Presser; Kristopher A Sarosiek
Journal:  Int Rev Cell Mol Biol       Date:  2018-08-29       Impact factor: 6.813

Review 3.  DNA vaccines, electroporation and their applications in cancer treatment.

Authors:  Si-Hyeong Lee; Sayyed Nilofar Danishmalik; Jeong-Im Sin
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Addition of interleukin-12 to GA733 tumor protein vaccine leads to development of tumor protective immunity despite surgical stress.

Authors:  I Kirman; N Poltoratskaia; D Herlyn; R L Whelan
Journal:  Surg Endosc       Date:  2003-03-28       Impact factor: 4.584

5.  Myeloid Cell-Targeted Nanocarriers Efficiently Inhibit Cellular Inhibitor of Apoptosis for Cancer Immunotherapy.

Authors:  Peter D Koch; Christopher B Rodell; Rainer H Kohler; Mikael J Pittet; Ralph Weissleder
Journal:  Cell Chem Biol       Date:  2020-01-02       Impact factor: 8.116

Review 6.  Cytokine-adjuvanted HIV-DNA vaccination strategies.

Authors:  Franco Lori; David B Weiner; Sandra A Calarota; Laurene M Kelly; Julianna Lisziewicz
Journal:  Springer Semin Immunopathol       Date:  2006-10-20

7.  CD4+ and CD8+ T cells can act separately in tumour rejection after immunization with murine pneumotropic virus chimeric Her2/neu virus-like particles.

Authors:  Kalle Andreasson; Mathilda Eriksson; Karin Tegerstedt; Torbjörn Ramqvist; Tina Dalianis
Journal:  PLoS One       Date:  2010-07-19       Impact factor: 3.240

Review 8.  Interleukin 12: still a promising candidate for tumor immunotherapy?

Authors:  Witold Lasek; Radosław Zagożdżon; Marek Jakobisiak
Journal:  Cancer Immunol Immunother       Date:  2014-02-11       Impact factor: 6.968

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.